PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August9, 2017, Puma Biotechnology, Inc. issued a press release announcing its financial results for the quarter ended June30, 2017. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any filing to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
| Item 2.02 | Financial Statements and Exhibits. |
(d) Exhibits.
| 99.1 | Press Release dated August9, 2017 |
PUMA BIOTECHNOLOGY, INC. ExhibitEX-99.1 2 d438872dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2017 Financial Results LOS ANGELES,…To view the full exhibit click here
About PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.
